Yanyan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanyan Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Baoquan Lin
Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publication - Liya Pan
Department of Neurology, The Fourth Affiliated Hospital of Guangxi Medical University, China
1 shared publication - Mengqi Yang
Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publication - Qianqian Liu
Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publication - Shan Deng
Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publication - Shijian Chen
Department of Neurology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (28) , e49565
Clinical characteristics and prognosis of antibody-mediated autoimmune encephalitis: A single-center cohort study in Liuzhou, China
This retrospective observational study primarily aims to analyze the clinical characteristics and prognosis of patients with antibody-mediated autoimmune encephalitis (AE) in Liuzhou, China. We retrospectively reviewed the medical records of 32 patients diagnosed with acute AE between January 1, 2017, and August 31, 2024, for the following parameters: clinical features, results of laboratory and imaging studies, treatment, and clinical outcomes. Anti-N-methyl-d-aspartate receptor encephalitis was the most prevalent subtype (50%, 16/32). Other subtypes included glial fibrillary acidic protein astrocytopathy encephalitis (12.5%, 4/32), anti-myelin oligodendrocyte glycoprotein encephalitis (12.5%, 4/32), anti-leucine glioma inactivating protein 1 encephalitis (6.3%, 2/32), anti-GAD65 encephalitis (6.3%, 2/32), anti-GABABR encephalitis (6.3%, 2/32), and anti-contactin-associated protein-like 2 encephalitis (6.3%, 2/32). The most common prodromal manifestation were fever or influenza-like illness (56.25%). The primary clinical manifestations included seizures (25.68%), psychiatric and behavioral disorders (17.57%), disturbances in consciousness (9.46%), and dyssomnia (9.46%). Pneumonia, observed in 43.75% (14/32) of patients, was associated with older age ( P = .017), higher intensive care unit admission rates ( P = .042), increased need for mechanical ventilation ( P = .002), and worse modified Rankin Scale scores at diagnosis ( P = .005). Immunotherapy led to clinical improvement in most cases (78.13%), and these patients achieved favorable outcomes (modified Rankin Scale ≤ 2; median follow-up 37 months). In conclusion, the AE characteristics in our single-center retrospective study were consistent with previous findings. The proportion of anti- N -methyl- d -aspartate receptor encephalitis was the highest. Once AE is diagnosed, immunotherapy should be initiated promptly to reduce disease severity and improve outcomes. In clinical practice for AE management, emphasis should be placed on pneumonia prevention and treatment to reduce the rate of intensive care unit admission and mechanical ventilation and shorten the length of hospitalization.
- 10 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (28) , e49565
Open AccessClinical characteristics and prognosis of antibody-mediated autoimmune encephalitis: A single-center cohort study in Liuzhou, China
This retrospective observational study primarily aims to analyze the clinical characteristics and prognosis of patients with antibody-mediated autoimmune encephalitis (AE) in Liuzhou, China. We retrospectively reviewed the medical records of 32 patients diagnosed with acute AE between January 1, 2017, and August 31, 2024, for the following parameters: clinical features, results of laboratory and imaging studies, treatment, and clinical outcomes. Anti-N-methyl-d-aspartate receptor encephalitis was the most prevalent subtype (50%, 16/32). Other subtypes included glial fibrillary acidic protein astrocytopathy encephalitis (12.5%, 4/32), anti-myelin oligodendrocyte glycoprotein encephalitis (12.5%, 4/32), anti-leucine glioma inactivating protein 1 encephalitis (6.3%, 2/32), anti-GAD65 encephalitis (6.3%, 2/32), anti-GABABR encephalitis (6.3%, 2/32), and anti-contactin-associated protein-like 2 encephalitis (6.3%, 2/32). The most common prodromal manifestation were fever or influenza-like illness (56.25%). The primary clinical manifestations included seizures (25.68%), psychiatric and behavioral disorders (17.57%), disturbances in consciousness (9.46%), and dyssomnia (9.46%). Pneumonia, observed in 43.75% (14/32) of patients, was associated with older age ( P = .017), higher intensive care unit admission rates ( P = .042), increased need for mechanical ventilation ( P = .002), and worse modified Rankin Scale scores at diagnosis ( P = .005). Immunotherapy led to clinical improvement in most cases (78.13%), and these patients achieved favorable outcomes (modified Rankin Scale ≤ 2; median follow-up 37 months). In conclusion, the AE characteristics in our single-center retrospective study were consistent with previous findings. The proportion of anti- N -methyl- d -aspartate receptor encephalitis was the highest. Once AE is diagnosed, immunotherapy should be initiated promptly to reduce disease severity and improve outcomes. In clinical practice for AE management, emphasis should be placed on pneumonia prevention and treatment to reduce the rate of intensive care unit admission and mechanical ventilation and shorten the length of hospitalization.